| 000 | 01819 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250514021517.0 | ||
| 264 | 0 | _c20020417 | |
| 008 | 200204s 0 0 eng d | ||
| 022 | _a0114-5916 | ||
| 024 | 7 |
_a10.2165/00002018-200124150-00005 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aClark, D W | |
| 245 | 0 | 0 |
_aProfiles of hepatic and dysrhythmic cardiovascular events following use of fluoroquinolone antibacterials: experience from large cohorts from the Drug Safety Research Unit Prescription-Event Monitoring database. _h[electronic resource] |
| 260 |
_bDrug safety _c2001 |
||
| 300 |
_a1143-54 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAnti-Infective Agents _xadverse effects |
| 650 | 0 | 4 |
_aArrhythmias, Cardiac _xchemically induced |
| 650 | 0 | 4 | _aChemical and Drug Induced Liver Injury |
| 650 | 0 | 4 |
_aCiprofloxacin _xadverse effects |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aDatabases, Factual |
| 650 | 0 | 4 |
_aDrug Monitoring _xmethods |
| 650 | 0 | 4 |
_aEngland _xepidemiology |
| 650 | 0 | 4 |
_aEnoxacin _xadverse effects |
| 650 | 0 | 4 | _aFamily Practice |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLiver Diseases _xepidemiology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNorfloxacin _xadverse effects |
| 650 | 0 | 4 |
_aOfloxacin _xadverse effects |
| 650 | 0 | 4 |
_aProduct Surveillance, Postmarketing _xmethods |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aSurveys and Questionnaires |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aLayton, D | |
| 700 | 1 | _aWilton, L V | |
| 700 | 1 | _aPearce, G L | |
| 700 | 1 | _aShakir, S A | |
| 773 | 0 |
_tDrug safety _gvol. 24 _gno. 15 _gp. 1143-54 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2165/00002018-200124150-00005 _zAvailable from publisher's website |
| 999 |
_c11684208 _d11684208 |
||